Compare Stocks: ACLX, ROIV, INCY, and MRNA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACLX Arcellx	$115.07	$114.67	$47.86 ▼ $115.13	$6.73B	0.25	1.50 million shs	14.67 million shs
INCY Incyte	$127.22 -1.0%	$115.79	$81.09 ▼ $132.60	$26.04B	0.76	1.87 million shs	1.21 million shs
MRNA Moderna	$133.32 -23.5%	$66.58	$22.28 ▼ $176.66	$53.23B	0.91	15.14 million shs	99.07 million shs
ROIV Roivant Sciences	$36.84 -1.5%	$34.48	$11.54 ▼ $37.97	$27.01B	1.12	5.69 million shs	3.13 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACLX Arcellx	0.00%	0.00%	0.00%	0.00%	+60.91%
INCY Incyte	-0.97%	+5.56%	+8.37%	+30.94%	+47.59%
MRNA Moderna	-23.55%	+109.46%	+123.47%	+184.39%	+395.80%
ROIV Roivant Sciences	-1.50%	+1.54%	+5.38%	+22.96%	+214.33%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACLX Arcellx	$115.07	$114.67	$47.86 ▼ $115.13	$6.73B	0.25	1.50 million shs	14.67 million shs
INCY Incyte	$127.22 -1.0%	$115.79	$81.09 ▼ $132.60	$26.04B	0.76	1.87 million shs	1.21 million shs
MRNA Moderna	$133.32 -23.5%	$66.58	$22.28 ▼ $176.66	$53.23B	0.91	15.14 million shs	99.07 million shs
ROIV Roivant Sciences	$36.84 -1.5%	$34.48	$11.54 ▼ $37.97	$27.01B	1.12	5.69 million shs	3.13 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACLX Arcellx	0.00%	0.00%	0.00%	0.00%	+60.91%
INCY Incyte	-0.97%	+5.56%	+8.37%	+30.94%	+47.59%
MRNA Moderna	-23.55%	+109.46%	+123.47%	+184.39%	+395.80%
ROIV Roivant Sciences	-1.50%	+1.54%	+5.38%	+22.96%	+214.33%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACLX Arcellx	2.06	Hold	$110.36	-4.10% Downside
INCY Incyte	2.48	Hold	$123.10	-3.24% Downside
MRNA Moderna	2.00	Hold	$66.25	-50.31% Downside
ROIV Roivant Sciences	2.83	Moderate Buy	$35.14	-4.62% Downside

Current Analyst Ratings Breakdown

Latest ACLX, ROIV, INCY, and MRNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2026	INCY Incyte	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/20/2026	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$50.00 ➝ $150.00
8/20/2026	INCY Incyte	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$152.00
8/20/2026	INCY Incyte	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$150.00
8/20/2026	MRNA Moderna	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$39.00 ➝ $89.00
8/19/2026	MRNA Moderna	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/19/2026	ROIV Roivant Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/19/2026	MRNA Moderna	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$67.00 ➝ $120.00
8/19/2026	MRNA Moderna	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sector Perform	$130.00
8/19/2026	MRNA Moderna	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$135.00
8/19/2026	MRNA Moderna	Brookline Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 8/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACLX Arcellx	$22.29M	301.95	N/A	N/A	$6.96 per share	16.53
INCY Incyte	$5.82B	4.43	$6.12 per share	20.79	$31.30 per share	4.06
MRNA Moderna	$2.21B	24.08	N/A	N/A	$16.93 per share	7.87
ROIV Roivant Sciences	$8.26M	3,221.58	N/A	N/A	$6.81 per share	5.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACLX Arcellx	-$228.93M	-$4.07	N/A	N/A	N/A	-1,027.26%	-55.42%	-36.24%	N/A
INCY Incyte	$1.29B	$7.85	16.21	15.78	4.07	27.71%	29.93%	22.88%	10/27/2026 (Estimated)
MRNA Moderna	-$2.82B	-$7.99	N/A	N/A	N/A	-141.43%	-28.30%	-19.39%	11/5/2026 (Estimated)
ROIV Roivant Sciences	-$299.77M	-$0.53	N/A	N/A	N/A	-3,534.96%	-22.94%	-21.53%	11/9/2026 (Estimated)

Latest ACLX, ROIV, INCY, and MRNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2026	Q1 2027	ROIV Roivant Sciences	-$0.2996	-$0.26	+$0.0396	-$0.26	$2.06 million	$1.44 million
7/31/2026	Q2 2026	MRNA Moderna	-$2.03	-$1.97	+$0.06	-$1.97	$102.93 million	$145.00 million
7/28/2026	Q2 2026	INCY Incyte	$2.15	$3.09	+$0.94	$2.81	$1.50 billion	$1.67 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACLX Arcellx	N/A	N/A	N/A	N/A	N/A
INCY Incyte	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACLX Arcellx	N/A	4.44	4.44
INCY Incyte	N/A	4.59	4.51
MRNA Moderna	0.09	2.29	2.18
ROIV Roivant Sciences	N/A	16.72	16.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACLX Arcellx	96.03%
INCY Incyte	96.97%
MRNA Moderna	75.33%
ROIV Roivant Sciences	64.76%

Insider Ownership

Company	Insider Ownership
ACLX Arcellx	8.35%
INCY Incyte	16.20%
MRNA Moderna	10.80%
ROIV Roivant Sciences	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACLX Arcellx	80	58.48 million	53.60 million	Optionable
INCY Incyte	2,844	202.70 million	169.86 million	Optionable
MRNA Moderna	4,700	399.24 million	356.12 million	Optionable
ROIV Roivant Sciences	860	722.32 million	658.76 million	Optionable

ACLX, ROIV, INCY, and MRNA Headlines

Recent News About These Companies

107,786 Shares in Roivant Sciences Ltd. $ROIV Purchased by Great Lakes Advisors LLC

3 hours ago | marketbeat.com

Mayukh Sukhatme Sells 136,942 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

August 19 at 5:36 AM | insidertrades.com

Roivant Sciences (NASDAQ:ROIV) Sets New 52-Week High - Should You Buy?

August 19 at 4:01 AM | americanbankingnews.com

Insider Selling: Roivant Sciences (NASDAQ:ROIV) Insider Sells 136,942 Shares

August 18 at 9:06 PM | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Insider Mayukh Sukhatme Sells 243,177 Shares

August 18 at 9:06 PM | marketbeat.com

Mayukh Sukhatme Sells 284,707 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

August 18 at 9:06 PM | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Rating of "Moderate Buy" from Brokerages

August 18 at 4:13 AM | marketbeat.com

Why Is Roivant (NASDAQ:ROIV) a Nasdaq Healthcare Stock to Watch?

August 17, 2026 | kalkinemedia.comK

Roivant Sciences (NASDAQ:ROIV) Sets New 1-Year High - Here's Why

August 17, 2026 | marketbeat.com

Royal Bank of Canada Decreases Position in Roivant Sciences Ltd. $ROIV

August 16, 2026 | marketbeat.com

Empowered Funds LLC Buys 267,686 Shares of Roivant Sciences Ltd. $ROIV

August 16, 2026 | marketbeat.com

Handelsbanken Fonder AB Has $6.27 Million Position in Roivant Sciences Ltd. $ROIV

August 15, 2026 | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Price Target Raised to $42.00

August 10, 2026 | americanbankingnews.com

Bank of America Corp DE Has $87.64 Million Stock Position in Roivant Sciences Ltd. $ROIV

August 9, 2026 | marketbeat.com

Roivant Sciences: The Balance Sheet Has Become A Strategic Weapon

August 8, 2026 | seekingalpha.com

Sei Investments Co. Acquires 33,508 Shares of Roivant Sciences Ltd. $ROIV

August 8, 2026 | marketbeat.com

Guggenheim Issues Positive Forecast for Roivant Sciences (NASDAQ:ROIV) Stock Price

August 7, 2026 | marketbeat.com

Roivant Sciences Q1 Earnings Call Highlights

August 7, 2026 | marketbeat.com

Assenagon Asset Management S.A. Acquires 1,286,464 Shares of Roivant Sciences Ltd. $ROIV

August 7, 2026 | marketbeat.com

Roivant outlines brepocitinib DM launch by end of September and targets cutaneous sarcoidosis Phase III data in 2028

August 6, 2026 | seekingalpha.com

Roivant Sciences Ltd. (ROIV) Q1 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ACLX, ROIV, INCY, and MRNA Company Descriptions

Arcellx NASDAQ:ACLX

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Incyte NASDAQ:INCY

$127.22 -1.25 (-0.97%)

Closing price 08/20/2026 04:00 PM Eastern

Extended Trading

$126.97 -0.25 (-0.20%)

As of 07:27 AM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Moderna NASDAQ:MRNA

$133.32 -41.06 (-23.55%)

Closing price 08/20/2026 04:00 PM Eastern

Extended Trading

$135.75 +2.43 (+1.82%)

As of 07:32 AM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Roivant Sciences NASDAQ:ROIV

$36.84 -0.56 (-1.50%)

Closing price 08/20/2026 04:00 PM Eastern

Extended Trading

$37.15 +0.31 (+0.85%)

As of 07:31 AM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACLX, ROIV, INCY, and MRNA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACLX, ROIV, INCY, and MRNA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACLX, ROIV, INCY, and MRNA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ACLX, ROIV, INCY, and MRNA Company Descriptions

Arcellx NASDAQ:ACLX

Incyte NASDAQ:INCY

Moderna NASDAQ:MRNA

Roivant Sciences NASDAQ:ROIV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACLX, ROIV, INCY, and MRNA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACLX, ROIV, INCY, and MRNA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACLX, ROIV, INCY, and MRNA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ACLX, ROIV, INCY, and MRNA Company Descriptions

Arcellx NASDAQ:ACLX

Incyte NASDAQ:INCY

Moderna NASDAQ:MRNA

Roivant Sciences NASDAQ:ROIV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools